TABLE 1.
Patient characteristics and comparison between patients stratified for age (18–39 years, 40–69 years, ≥70 years)
| Patient characteristics | All patients(n = 900) | Age | p‐value | ||
|---|---|---|---|---|---|
| 18–39 years(n = 290) | 40–69 years(n = 357) | ≥70 years(n = 253) | |||
| Sex, male/female (% male) | 472/428 (52.4%) | 151/139 (52.1%) | 204/153 (57.1%) | 117/136 (46.2%) | .029 |
| Age, years (IQR) | 52.9 (37.3) | 29.6 (9.4) | 55.4 (13.3) | 79.8 (9.7) | <.001 |
| Obesity, n/n total (%) | 143/390 (36.7%) | 24/69 (34.8%) | 110/198 (44.4%) | 31/123 (25.2%) | .002 |
| Liver disease, n/n total (%) | 60/741 (8.1%) | 2/198 (1.0%) | 27/298 (9.1%) | 31/245 (12.7%) | <.001 |
| Arterial Hypertension, n/n total (%) | 323/738 (44.4%) | 9/198 (13.3%) | 129/295 (43.7%) | 185/245 (75.5%) | <.001 |
| Diabetes mellitus, n/n total (%) | 141/740 (19.1%) | 5/198 (2.5%) | 68/296 (23.0%) | 68/246 (27.6%) | <.001 |
| Dyslipidemia, n/n total (%) | 158/741 (21.3%) | 7/198 (3.5%) | 61/297 (20.5%) | 90/246 (36.6%) | <.001 |
| Cardiovascular disease, n/n total (%) | 215/737 (29.2%) | 6/198 (3.0%) | 57/293 (19.5%) | 152/246 (61.8%) | <0.001 |
| Chronic renal insufficiency, n/n total (%) | 91/751 (12.1%) | 1/201 (0.5%) | 23/303 (7.6%) | 67/247 (27.1%) | <.001 |
| Lung disease, n/n total (%) | 126/743 (17.0%) | 11/198 (5.6%) | 53/298 (17.8%) | 62/247 (25.1%) | <.001 |
| Malignancy, n/n total (%) | 111/741 (15.0%) | 4/200 (2.0%) | 48/296 (16.2%) | 59/245 (24.1%) | <.001 |
| Liver injury, n/n total (%) a | 66/652 (10.3%) | 11/130 (8.5%) | 45/282 (16.0%) | 11/240 (4.6%) | <.001 |
| Alkaline phosphatase, U × L−1 (IQR) a | 72.5 (46.0) | 65.0 (34.0) | 73.0 (51.0) | 75.0 (53.0) | .080 |
| Alkaline phosphatase > 2xULN, n/n total (%) | 27/558 (4.8%) | 2/117 (1.7%) | 21/261 (8.0%) | 4/180 (2.2%) | .004 |
| Aspartate transaminase, U × L−1 (IQR) a | 32.0 (30.0) | 27.0 (20.0) | 34.0 (32.0) | 33.0 (29.0) | .044 |
| Aspartate transaminase > 3xULN, n/n total (%) a | 23/618 (3.7%) | 5/121 (4.1%) | 13/275 (4.7%) | 5/222 (2.3%) | .338 |
| Alanine aminotransferase, U × L−1 (IQR) a | 27.0 (25.0) | 28.0 (28.0) | 30.0 (32.8) | 23.0 (18.0) | .001 |
| Alanine aminotransferase > 3xULN, n/n total (%) a | 28/648 (4.3%) | 8/130 (6.2%) | 15/280 (5.4%) | 5/238 (2.1%) | .099 |
| Gamma‐glutamyl transferase, U × L−1 (IQR) a | 42.0 (84.5) | 28.0 (57.5) | 53.0 (143.0) | 42.0 (62.0) | <.001 |
| Gamma‐glutamyl transferase > 2xULN, n/Total n (%) a | 145/565 (25.7%) | 18/117 (15.4%) | 89/261 (34.1%) | 38/187 (20.3%) | <.001 |
| Bilirubin, mg × dl−1 (IQR) a | 0.5 (0.4) | 0.4 (0.3) | 0.5 (0.5) | 0.5 (0.3) | .137 |
| Bilirubin > 2xULN, n/n total (%) a | 23/638 (3.6%) | 3/124 (2.4%) | 17/275 (6.2%) | 3/236 (1.3%) | .009 |
| Thrombocytes, G × L−1 (IQR) a | 213.5 (107.0) | 229.5 (79.8) | 218.0 (114.0) | 203.0 (112.0) | .005 |
| D‐dimer, mg × dl−1 (IQR) a | 1.5 (2.6) | 0.5 (0.8) | 1.3 (2.8) | 1.3 (2.5) | <.001 |
| Albumin, g × L−1 (IQR) a | 33.7 (11.6) | 42.7 (13.6) | 32.7 (12.0) | 32.6 (7.9) | <.001 |
| Creatinine, mg × dl−1 (IQR) a | 0.9 (0.5) | 0.8 (0.3) | 0.8 (0.4) | 1.0 (0.7) | <.001 |
| C‐reactive pr/otein, mg × dl−1 (IQR) a | 2.6 (8.1) | 1.0 (3.3) | 3.3 (9.6) | 3.2 (7.3) | <.001 |
| Follow‐up and clinical outcomes | All patients (n = 697) | Age | p‐value | ||
|---|---|---|---|---|---|
| 18–39 years (n = 175) | 40–69 years (n = 293) | ≥70 years (n = 229) | |||
| Median follow‐up, days (IQR) | 63.0 (139.0) | ||||
| Hospital admission, n (%) | 458 (65.7%) | 52 (29.7%) | 200 (68.3%) | 206 (90.0%) | <.001 |
| Median hospital stay, days (IQR) | 22.0 (33.0) | 12.0 (25.0) | 25.5 (39.0) | 21.0 (28.0) | .011 |
| ICU admission, n (%) | 200 (28.7%) | 23 (13.1%) | 126 (43.0%) | 51 (22.3%) | <.001 |
| Median ICU stay, days (IQR) | 22.0 (30.0) | 18.0 (20.0) | 29.0 (32.0) | 11.0 (19.0) | .002 |
| Intubation, n (%) | 164 (23.5%) | 17 (9.7%) | 108 (36.9%) | 39 (17.0%) | <.001 |
| Median duration of intubation, days (IQR) | 21.5 (29.0) | 19.0 (14.0) | 26.5 (31.0) | 13.0 (19.0) | .001 |
| Death, n (%) | 154 (22.1%) | 0 (0.0%) | 61 (20.8%) | 93 (40.6%) | <.001 |
| COVID‐19‐related death, n (%) | 128 (18.4%) | 0 (0.0%) | 45 (15.4%) | 83 (36.2%) | <.001 |
| Liver‐related death, n (%) | 24 (2.7%) | 0 (0.0%) | 19 (6.5%) | 5 (2.2%) | <.001 |
a
At the first blood withdrawal after the first positive SARS‐CoV‐2 PCR test.
p‐values depicting statistically significant differences are presented as bold values.